A Phase 3 interventional study of Remdesivir and Standard of Care in COVID-19, sponsored by Gilead Sciences. Completed at 184 sites in 15 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-01-26.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing remdesivir in COVID-19 — 6 open to participants now, 9 under way, 3 of them phase 3. remdesivir · COVID-19.
Among the 40 studies testing remdesivir in COVID-19, this one is the 9th largest by enrollment, is one of 27 that started in 2020, is one of 17 in phase 3, and was the 5th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →6 of the 40 studies testing remdesivir in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia · Sites in Spain
Ages 18+
Pfizer · Sites in United States, Argentina, Belgium and 15 more countries
Ages 18+
ANRS, Emerging Infectious Diseases · Sites in France, Italy, Norway
Ages 16+
University of Oxford · Sites in Brazil, Laos, Nepal and 2 more countries
Ages 18–60
Lebanese University · Sites in Lebanon
Ages 18+
By country, each count listing its studies:
remdesivir: first FDA approval 2020 (VEKLURY), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 12 · Phase 3 22 · Phase 4 5
First in 2016; this study’s year is marked. 27 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,113 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 283 across the 40 interventional studies. Of the 20 that completed or were terminated, 10 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 40 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
10 studies in COVID-19 by Gilead Sciences: none open now, none under way, none of them phase 3. Of 9 finished, 9 (100%) have results posted.
Among the 10 studies in COVID-19 by Gilead Sciences, this one is one of 5 that started in 2020, is one of 6 in phase 3, and was the 1st registered.
Gilead Sciences’s COVID-19 studies by the year they started, since 2020.
4 of the studies testing remdesivir in COVID-19 that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT07197164Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la CienciaSafety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant Patients | 2026-12-30 |
| NCT05587894ANRS, Emerging Infectious DiseasesOPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial | 2026-12-31 |
| NCT05041907University of OxfordFinding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) | 2027-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 40 studies testing remdesivir in COVID-19, from their registry updates:
Among Gilead Sciences’s 10 in COVID-19:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study was to evaluate the efficacy of 2 remdesivir (RDV) regimens compared to standard of care (SOC), with respect to clinical status assessed by a 7-point ordinal scale on Day 11.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive continued standard of care (SOC) therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.
Drug: Remdesivir · Drug: Standard of Care
Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.
Drug: Remdesivir · Drug: Standard of Care
Participants will receive continued standard of care therapy.
Drug: Standard of Care
Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.
Drug: Remdesivir · Drug: Standard of Care
Administered as an intravenous infusion
Also known as: GS-5734™, Veklury®
Standard of Care Treatment for COVID-19 Infection
Part A: Percentage of Participants in Each Clinical Status Category as Assessed by a 7-Point Ordinal Scale on Day 11
Clinical status was derived from death, hospital discharge, and ordinal scale as follows: score of "1" was used for all days on or after the date of death; score of "7" was used for all days on or after discharged alive date; last available assessment for missing value. The scale is as follows: 1. Death; 2. Hospitalized, on invasive mechanical ventilation or Extracorporeal Membrane Oxygenation (ECMO); 3. Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring low flow supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (coronavirus (COVID-19) related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer required ongoing medical care (other than per protocol remdesivir administration; 7. Not hospitalized. The odds ratio represents the odds of improvement in the ordinal scale for a RDV group relative to the SOC group.
Time frame: Day 11
Part A: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs)
TEAEs were defined as the following: any AE with an onset date on or after the study treatment start date and no later than 30 days after permanent discontinuation of study treatment and/or any AE leading to premature discontinuation of study treatment. For participants randomized to the SOC group, all AEs reported on or after the protocol-specified Day 1 visit were considered as treatment emergent.
Time frame: First dose date up to last dose date (maximum: 10 days) plus 30 days
Participants were enrolled at study sites in the United States, Europe, and Asia. The first participant was screened on 15 March 2020. The last study visit occurred on 26 June 2020.
| Milestone | Part A: Remdesivir (RDV) for 5 Days | Part A: Remdesivir for 10 Days | Part A: SOC Therapy | Part B: Extension Treatment, Remdesivir for 10 Days |
|---|---|---|---|---|
| Started | 199 | 197 | 200 | 517 |
| Completed | 179 | 176 | 178 | 437 |
| Not completed | 20 | 21 | 22 | 80 |
| Withdrew: Lost to follow-up | 8 | 12 | 12 | 48 |
| Withdrew: Death | 2 | 2 | 4 | 12 |
| Withdrew: Withdrew consent | 2 | 2 | 5 | 6 |
| Withdrew: Non-compliance with study drug | 0 | 1 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 |
| Withdrew: Randomized but not treated | 8 | 4 | 0 | 14 |
Clinical status was derived from death, hospital discharge, and ordinal scale as follows: score of "1" was used for all days on or after the date of death; score of "7" was used for all days on or after discharged alive date; last available assessment for missing value. The scale is as follows: 1. Death; 2. Hospitalized, on invasive mechanical ventilation or Extracorporeal Membrane Oxygenation (ECMO); 3. Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring low flow supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (coronavirus (COVID-19) related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer required ongoing medical care (other than per protocol remdesivir administration; 7. Not hospitalized. The odds ratio represents the odds of improvement in the ordinal scale for a RDV group relative to the SOC group.
| percentage of participants | Part A: Remdesivir for 5 Days | Part A: Remdesivir for 10 Days | Part A: SOC Therapy |
|---|---|---|---|
| Score: 1 | 0.0 | 1.0 | 2.0 |
| Score: 2 | 0.0 | 0.5 | 2.0 |
| Score: 3 | 2.6 | 0.0 | 3.5 |
| Score: 4 | 3.7 | 6.2 | 5.5 |
| Score: 5 | 19.9 | 22.8 | 23.0 |
| Score: 6 | 3.7 | 4.7 | 4.0 |
| Score: 7 | 70.2 | 64.8 | 60.0 |
TEAEs were defined as the following: any AE with an onset date on or after the study treatment start date and no later than 30 days after permanent discontinuation of study treatment and/or any AE leading to premature discontinuation of study treatment. For participants randomized to the SOC group, all AEs reported on or after the protocol-specified Day 1 visit were considered as treatment emergent.
| percentage of participants | Part A: Remdesivir for 5 Days | Part A: Remdesivir for 10 Days | Part A: SOC Therapy |
|---|---|---|---|
| Part A: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs) | 51.3 (44.0 to 58.6) | 58.5 (51.3 to 65.6) | 46.5 (39.4 to 53.7) |
Collected over First dose date up to the last dose date (maximum: 10 days for Part A, 11 days for Part B) plus 30 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Remdesivir for 5 Days | 2/191 (1%) | 9/191 (4.7%) | 41/191 (21.5%) |
| Part A: Remdesivir for 10 Days | 3/193 (1.6%) | 10/193 (5.2%) | 42/193 (21.8%) |
| Part A: SOC Therapy | 4/200 (2%) | 18/200 (9%) | 30/200 (15%) |
| Part B: Extension Treatment, Remdesivir for 10 Days | 13/503 (2.6%) | 40/503 (8%) | 113/503 (22.5%) |
| Event | Part A: Remdesivir for 5 Days | Part A: Remdesivir for 10 Days | Part A: SOC Therapy | Part B: Extension Treatment, Remdesivir for 10 Days |
|---|---|---|---|---|
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/191 | 1/193 | 5/200 | 4/503 |
| Respiratory distressRespiratory, thoracic and mediastinal disorders | 0/191 | 2/193 | 2/200 | 1/503 |
| Cardiac arrestCardiac disorders | 0/191 | 0/193 | 2/200 | 0/503 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/191 | 0/193 | 2/200 | 1/503 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/191 | 0/193 | 0/200 | 0/503 |
| Impaired healingGeneral disorders | 1/191 | 0/193 | 0/200 | 0/503 |
| Pneumonia bacterialInfections and infestations | 1/191 | 0/193 | 0/200 | 0/503 |
| Heart rate decreasedInvestigations | 1/191 | 0/193 | 0/200 | 0/503 |
| Cerebrovascular accidentNervous system disorders | 1/191 | 0/193 | 0/200 | 0/503 |
| Renal colicRenal and urinary disorders | 1/191 | 0/193 | 0/200 | 0/503 |
| Event | Part A: Remdesivir for 5 Days | Part A: Remdesivir for 10 Days | Part A: SOC Therapy | Part B: Extension Treatment, Remdesivir for 10 Days |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 19/191 | 18/193 | 6/200 | 41/503 |
| DiarrhoeaGastrointestinal disorders | 12/191 | 10/193 | 14/200 | 28/503 |
| HypokalaemiaMetabolism and nutrition disorders | 10/191 | 13/193 | 4/200 | 23/503 |
| HeadacheNervous system disorders | 10/191 | 10/193 | 5/200 | 27/503 |
| ConstipationGastrointestinal disorders | 8/191 | 5/193 | 9/200 | 26/503 |
Part A: Safety Analysis Set included participants who were randomized into part A of the study and received at least 1 dose of study treatment or completed the Day 1 visit (SOC only group). Part B: Expanded RDV-Treated Analysis Set included participants who were enrolled into Part B of the study and received at least 1 dose of study drug.
| Age, Customized(Participants) | Part A: Remdesivir for 5 Days | Part A: Remdesivir for 10 Days | Part A: SOC Therapy | Part B: Extension Treatment, Remdesivir for 10 Days | Total |
|---|---|---|---|---|---|
| Age, Categorical — < 65 Years | 142 | 141 | 142 | 351 | 776 |
| Age, Categorical — >= 65 Years | 49 | 52 | 58 | 152 | 311 |
| Sex: Female, Male(Participants) | Part A: Remdesivir for 5 Days | Part A: Remdesivir for 10 Days | Part A: SOC Therapy | Part B: Extension Treatment, Remdesivir for 10 Days | Total |
|---|---|---|---|---|---|
| Female | 77 | 75 | 75 | 221 | 448 |
| Male | 114 | 118 | 125 | 282 | 639 |
| Race/Ethnicity, Customized(Participants) | Part A: Remdesivir for 5 Days | Part A: Remdesivir for 10 Days | Part A: SOC Therapy | Part B: Extension Treatment, Remdesivir for 10 Days | Total |
|---|---|---|---|---|---|
| Race — American Indian or Alaska Native | 2 | 0 | 1 | 3 | 6 |
| Race — Asian | 34 | 31 | 37 | 61 | 163 |
| Race — Black | 35 | 37 | 27 | 107 | 206 |
| Race — Native Hawaiian or Pacific Islander | 1 | 1 | 1 | 1 | 4 |
| Race — White | 109 | 107 | 112 | 260 | 588 |
| Race — Not Permitted | 5 | 5 | 7 | 21 | 38 |
| Race — Other | 5 | 12 | 15 | 50 | 82 |
| Race/Ethnicity, Customized(Participants) | Part A: Remdesivir for 5 Days | Part A: Remdesivir for 10 Days | Part A: SOC Therapy | Part B: Extension Treatment, Remdesivir for 10 Days | Total |
|---|---|---|---|---|---|
| Ethnicity — Hispanic or Latino | 25 | 42 | 34 | 156 | 257 |
| Ethnicity — Not Hispanic or Latino | 162 | 144 | 152 | 325 | 783 |
| Ethnicity — Not Permitted | 4 | 7 | 13 | 22 | 46 |
| Ethnicity — Missing | 0 | 0 | 1 | 0 | 1 |
| Region of Enrollment(Participants) | Part A: Remdesivir for 5 Days | Part A: Remdesivir for 10 Days | Part A: SOC Therapy | Part B: Extension Treatment, Remdesivir for 10 Days | Total |
|---|---|---|---|---|---|
| United States | 76 | 99 | 85 | 318 | 578 |
| Spain | 37 | 28 | 31 | 44 | 140 |
| Italy | 30 | 23 | 26 | 54 | 133 |
| United Kingdom | 7 | 9 | 17 | 27 | 60 |
| South Korea | 7 | 4 | 10 | 16 | 37 |
| Germany | 8 | 6 | 8 | 13 | 35 |
| Singapore | 3 | 6 | 9 | 14 | 32 |
| Hong Kong | 9 | 11 | 7 | 1 | 28 |
| Switzerland | 4 | 5 | 6 | 3 | 18 |
| France | 2 | 1 | 0 | 5 | 8 |
| Taiwan | 5 | 1 | 0 | 0 | 6 |
| Netherlands | 3 | 0 | 1 | 1 | 5 |
| Japan | 0 | 0 | 0 | 4 | 4 |
| Sweden | 0 | 0 | 0 | 3 | 3 |
Showing the first 100 of 184 sites across 15 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
Ran from Mar 2020 to primary completion in Apr 2020, 1 month.
Results were first posted in Jan 2021, 8 months after primary completion.
Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 1 month is below that.
Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Remdesivir